ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.15
-0.07 (-0.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.22
Open11.26
Bid11.10 x 1000
Ask11.30 x 100
Day's Range11.09 - 11.34
52 Week Range5.27 - 12.54
Volume1,829,672
Avg. Volume6,386,154
Market Cap2.495B
Beta-0.17
PE Ratio (TTM)N/A
EPS (TTM)-10.60
Earnings DateAug 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.09
Trade prices are not sourced from all markets
  • PR Newswire21 hours ago

    Endo to Announce Second-Quarter 2018 Financial Results

    DUBLIN , July 20, 2018 /PRNewswire/ --   Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2018 financial results on August 8, 2018 and members of its senior management team will host ...

  • Drug Firms Blame Opioid Crisis on Illicit Websites, Dealers
    Bloomberg2 days ago

    Drug Firms Blame Opioid Crisis on Illicit Websites, Dealers

    Two pharmaceutical companies say the real culprits in the opioids epidemic are illegal dealers of the painkillers and want them to be on the hook financially for any damages potentially assessed against drugmakers. Endo International Plc and Mallinckrodt Plc sued a host of convicted drug dealers and Internet sites this week for illegally offering opioids. Among them: RxCash.Biz, which offers misbranded opioids online, an Italian man indicted for of operating so-called pill mills, and a Tennessee resident who’s serving 10 years for possessing fentanyl with an intent to distribute.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Endo International

    NEW YORK, NY / ACCESSWIRE / July 19, 2018 / U.S. equities closed mostly higher Wednesday, as investors welcomed quarterly earnings and positive signs of a rapidly growing domestic economy. The Dow Jones ...

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 17. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $2.05 billion.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $2.43 billion.

  • What Endo International’s Valuation Trend Indicates
    Market Realist9 days ago

    What Endo International’s Valuation Trend Indicates

    Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.

  • Endo’s Generic and International Segments Declined in Q1 2018
    Market Realist9 days ago

    Endo’s Generic and International Segments Declined in Q1 2018

    Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.

  • Analyzing Endo International’s Financial Performance
    Market Realist9 days ago

    Analyzing Endo International’s Financial Performance

    Endo International (ENDP) generated revenues of $700.5 million in the first quarter compared to $1.04 billion in Q1 2017. Endo International incurred a cost of revenues of $403.59 million in the first quarter compared to $668.96 million in Q1 2017. Its gross profit was $296.93 million in the first quarter compared to $368.64 million in Q1 2017.

  • Endo International’s Specialty and Established Products in Q1
    Market Realist9 days ago

    Endo International’s Specialty and Established Products in Q1

    Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.

  • What Analysts Think of Endo International
    Market Realist9 days ago

    What Analysts Think of Endo International

    Of the 19 analysts covering Endo International (ENDP) stock in July, four of them have given the stock a “buy” or higher rating, 14 have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.74 with a target price of $8.53. Sixteen of the 20 analysts covering Abbott Laboratories (ABT) in July have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $69.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: Endo International and GW Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...

  • ACCESSWIRE12 days ago

    Today's Research Reports on Trending Tickers: OPKO Health and Endo International

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...

  • ACCESSWIRE12 days ago

    Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

    Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $3.08 billion.

  • Is Endo International a Great Stock for Value Investors?
    Zacks18 days ago

    Is Endo International a Great Stock for Value Investors?

    Let???s see if Endo International (ENDP) stock is a good choice for value-oriented investors right now from multiple angles.

  • PR Newswire19 days ago

    Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States

    DUBLIN, July 2, 2018 /PRNewswire/ -- Endo International plc (ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys® (colchicine, USP) 0.6 mg tablets.  Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and distribution agreement with Takeda Pharmaceuticals U.S.A., allowing Par to launch and distribute an authorized generic of the product.

  • Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
    Zacks22 days ago

    Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

    Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

  • ACCESSWIRE22 days ago

    Today's Research Reports on Trending Tickers: Endo International and Sangamo Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...

  • Benzinga23 days ago

    Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity

    Endo International PLC (NASDAQ: ENDP ) is now trading at a favorable risk-reward profile and investors should be constructive on the stock, according to Citi. The Analyst Citi's Liav Abraham upgraded Endo ...

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play
    InvestorPlacelast month

    Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play

    The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.

  • Market Realistlast month

    Why Endo International Stock Rose 5.5% on June 12

    On June 11, after the markets closed, Endo International (ENDP) announced that its subsidiaries Endo Pharmaceuticals and Auxilium Pharmaceuticals have entered into a master settlement agreement. This agreement is intended to resolve all known TRT (testosterone replacement therapy) product liability claims the company faces. The company said that the agreement isn’t expected to increase Endo’s product liability reserve, as the company has already recorded an accrual for the settlement in Q4 2017.

  • CNBClast month

    Cramer's lightning round: I can't get people to buy Alibaba's stock

    Jim Cramer laments investors' distaste in the e-commerce conglomerate while taking questions in the lightning round.

  • Endo executes master settlement agreement to resolve testosterone lawsuits
    American City Business Journalslast month

    Endo executes master settlement agreement to resolve testosterone lawsuits

    Two Endo International subsidiaries, Endo Pharmaceuticals and Auxilium Pharmaceuticals, have executed a definitive master settlement agreement to resolve all known testosterone replacement therapy product liability claims against the company. The agreement does not involve any admission of wrongdoing or liability by Endo, which is based in Dublin, Ireland, and has its U.S. headquarters in Malvern, Pa. Endo and its subsidiaries are defendants in more than 1,200 lawsuits filed by users of testosterone replacement therapy, who have alleged the drug maker did not properly disclose health risks associated with taking such products. Endo was one of several testosterone replacement therapy manufacturers sued in such cases.

  • PR Newswirelast month

    Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order

    DUBLIN , June 11, 2018 /PRNewswire/ -- Endo International plc (NASDAQ:  ENDP ) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Auxilium Pharmaceuticals, LLC (collectively, "Endo" ...